Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 732

1.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ.

Clin Lung Cancer. 2013 Jul;14(4):418-24. doi: 10.1016/j.cllc.2012.10.003. Epub 2013 Jan 4.

PMID:
23291258
2.

A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.

Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y.

World J Surg Oncol. 2013 Mar 21;11:76. doi: 10.1186/1477-7819-11-76.

3.

Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.

Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB.

J Clin Oncol. 2003 May 1;21(9):1752-9.

PMID:
12721251
4.

A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).

Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, Saka H, Kurata T, Nishimura Y, Fukuoka M.

Cancer. 2012 Dec 15;118(24):6126-35. doi: 10.1002/cncr.26689. Epub 2012 Jun 6.

5.

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.

6.

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R.

J Clin Oncol. 2007 Oct 20;25(30):4736-42.

PMID:
17947721
7.

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group.

Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9.

8.

Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.

Paramanathan A, Solomon B, Collins M, Franco M, Kofoed S, Francis H, Ball D, Mileshkin L.

Clin Lung Cancer. 2013 Sep;14(5):508-12. doi: 10.1016/j.cllc.2013.03.007. Epub 2013 Jun 20.

PMID:
23792009
9.

Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group.

J Thorac Oncol. 2013 Feb;8(2):222-8. doi: 10.1097/JTO.0b013e3182774108.

10.

Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Decaluwé H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T.

Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.

PMID:
19502079
11.

The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.

Kim SH, Cho BC, Choi HJ, Chung KY, Kim DJ, Park MS, Kim SK, Chang J, Shin SJ, Sohn JH, Kim JH.

Lung Cancer. 2008 Jun;60(3):393-400. Epub 2007 Dec 26.

PMID:
18155802
12.

Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.

Dediu M, Ion O, Ion R, Alexandru A, Median D, Gal C, Horvat T, Motas C, Motas N.

J BUON. 2012 Apr-Jun;17(2):317-22.

PMID:
22740212
13.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
14.

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T.

Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.010. Epub 2011 Sep 3.

PMID:
21890422
15.

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.

Cancer. 1996 Jun 1;77(11):2393-9.

16.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group.

Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190. Epub 2015 Apr 23.

17.

The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.

Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, Kucharczuk JC, Lin L, Rengan R.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):340-7. doi: 10.1016/j.ijrobp.2011.05.070. Epub 2011 Nov 19.

PMID:
22104359
18.

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.

19.

[Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].

Zhang GQ, Han F, Gao SL, A DL, Pang ZL.

Ai Zheng. 2007 May;26(5):519-23. Chinese.

PMID:
17672944
20.

Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer.

Hamouda W, Dorgham Y, Yosry A, Abdel Wahab M.

Gulf J Oncolog. 2007 Jul;(2):55-64.

PMID:
20084725

Supplemental Content

Support Center